GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo International PLC (OTCPK:ENDPQ) » Definitions » Cash Flow from Operations

Endo International (Endo International) Cash Flow from Operations : $435 Mil (TTM As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Endo International Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Dec. 2023, Endo International's Net Income From Continuing Operations was $-2,441 Mil. Its Depreciation, Depletion and Amortization was $74 Mil. Its Change In Working Capital was $1,576 Mil. Its cash flow from deferred tax was $9 Mil. Its Cash from Discontinued Operating Activities was $0 Mil. Its Asset Impairment Charge was $0 Mil. Its Stock Based Compensation was $0 Mil. And its Cash Flow from Others was $897 Mil. In all, Endo International's Cash Flow from Operations for the three months ended in Dec. 2023 was $115 Mil.


Endo International Cash Flow from Operations Historical Data

The historical data trend for Endo International's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo International Cash Flow from Operations Chart

Endo International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 98.05 402.12 411.05 269.19 435.10

Endo International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 109.58 62.10 127.32 130.63 115.06

Endo International Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Endo International's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Endo International's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $435 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endo International  (OTCPK:ENDPQ) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Endo International's net income from continuing operations for the three months ended in Dec. 2023 was $-2,441 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Endo International's depreciation, depletion and amortization for the three months ended in Dec. 2023 was $74 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Endo International's change in working capital for the three months ended in Dec. 2023 was $1,576 Mil. It means Endo International's working capital increased by $1,576 Mil from Sep. 2023 to Dec. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Endo International's cash flow from deferred tax for the three months ended in Dec. 2023 was $9 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Endo International's cash from discontinued operating Activities for the three months ended in Dec. 2023 was $0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Endo International's asset impairment charge for the three months ended in Dec. 2023 was $0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Endo International's stock based compensation for the three months ended in Dec. 2023 was $0 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Endo International's cash flow from others for the three months ended in Dec. 2023 was $897 Mil.


Endo International Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Endo International's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Endo International (Endo International) Business Description

Traded in Other Exchanges
Address
Simmonscourt Road, Ballsbridge, First Floor, Minerva House, Dublin, IRL, 4
Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.
Executives
James Patrick Tursi officer: Executive VP, Global R&D 106 ASHLEY COURT, MOORESTOWN NJ 08057
Frank B. Raciti officer: VP, Controller and CAO C/O ENDO HEALTH SOLUTIONS INC., 1400 ATWATER DRIVE, MALVERN PA 19355
Shane Cooke director TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
William P Montague director
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
George Apostol officer: EVP, Head of Global R&D C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN 4 L2 00000
Mary Christine Smith director 3658 50TH AVE NE, SEATTLE WA 98105
Mark T. Bradley officer: EVP, Chief Financial Officer C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Mark G Barberio director 19 WIK STREET, WILLIAMSVILLE NY 14221
Jack D. Boyle officer: SVP, Interim Controller C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Roger H Kimmel director LATHAM & WATKINS, 885 THIRD AVENUE, NEW YORK NY 10022
Domenico Ciarico officer: EVP & Chief Commercial Officer C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Rahul Garella officer: EVP, Intl Pharmaceuticals C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Carrie Ann Nichol officer: VP, Controller & CAO 927 GRANDVIEW DRIVE, EXTON PA 19341

Endo International (Endo International) Headlines

From GuruFocus